Search Results
Your search for ,itS matches 8760 pages
Showing 8751 - 8760Inaugural Winners of the Breakthrough Prize in Life Sciences Announced
Founding sponsors Art Levinson, PhD, Sergey Brin, Anne Wojcicki, Mark Zuckerberg, Priscilla Chan, and Yuri Milner announced the launch of the Breakthrough Prize in Life Sciences, recognizing excellence in research aimed at curing intractable diseases and extending human life. The prize will be...
AACR Hosts Congressional Briefing on Cancer Progress, NIH Funding
The American Association for Cancer Research (AACR) hosted a briefing on February 12 for members of Congress and their legislative staffs that highlighted progress in cancer research and treatment as well as challenges created by decreased levels of funding. The briefing was held in the Rayburn...
Bevacizumab Significantly Improves Survival for Patients with Recurrent and Metastatic Cervical Cancer
Patients with advanced, recurrent, or persistent cervical cancer that was not curable with standard treatment who received the bevacizumab (Avastin) lived 3.7 months longer than patients who did not receive the drug, according to an interim analysis of a large, randomized clinical trial. The...
FDA Approval of Generic Version of Liposomal Doxorubicin Injection Is Expected to Help Resolve Shortage
The FDA has approved the first generic version of liposomal doxorubicin (Doxil), which is currently on the FDA’s drug shortage list. For products on the shortage list, the FDA’s Office of Generic Drugs is using a priority review system to expedite the review of generic applications to...
Alex’s Lemonade Stand Foundation Introduces Centers of Excellence Program to Further Childhood Cancer Research
Alex’s Lemonade Stand Foundation (ALSF), a registered 501(c)(3) charity, is furthering its commitment to finding cures for all children with cancer by introducing the ALSF Centers of Excellence program. The Centers of Excellence program aims to fund the research of leading childhood cancer...
Bevacizumab Approved as Combination Therapy for Metastatic Colorectal Cancer after Progression on First-line Bevacizumab Therapy
On January 23, 2013, the FDA approved bevacizumab (Avastin) for use in combination with fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin based chemotherapy for the treatment of patients with metastatic colorectal cancer whose disease has progressed on a first-line bevacizumab-containing...
Researchers Discover Promising Prognostic Marker for Aggressive Breast Cancer
A team of researchers led by Goutham Narla, MD, PhD, at Case Western Reserve University School of Medicine and University Hospitals Case Medical Center, and collaborators at the Mount Sinai School of Medicine and Erasmus Medical Center, have discovered a gene variant that drives the spread of...
Nab-paclitaxel plus Gemcitabine Demonstrates Survival Advantage in Phase III Study of Patients with Advanced Pancreatic Cancer
Celgene International Sàrl announced on Tuesday that its phase III clinical trial of paclitaxel protein-bound particles for injectable suspension, albumin-bound (nab-paclitaxel, Abaraxane) in combination with gemcitabine in treatment-naive patients with metastatic pancreatic cancer...
New Model May Help Predict Response to Chemotherapy for Colorectal Cancer
Scientists may be able to better predict which patients with colorectal cancer will respond to chemotherapy using a new mathematical model that measures the amount of stress required for a cancer cell to die without harming healthy tissue. The results of this study are published in Cancer Research, ...
Ezatiostat Gets Orphan Designation for Treatment of Myelodysplastic Syndrome
Telik, Inc, announced that its product candidate, ezatiostat hydrochloride (Telintra), has been granted orphan drug designation by the FDA for the treatment of myelodysplastic syndrome (MDS). Ezatiostat is an investigational agent in development for the treatment of MDS and idiopathic chronic...
